Lecanemab slows Alzheimer's disease: hope and challenges
- PMID: 36681438
- DOI: 10.1016/S1474-4422(22)00529-4
Lecanemab slows Alzheimer's disease: hope and challenges
Conflict of interest statement
NF reports consultancy services for Biogen, Eli Lilly, Ionis, and Roche (all payments to University College London) and has participated on a data safety monitoring board for Biogen. SM declares no competing interests.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
